Cozart clinches UK Home Office deal for confirmation DOA testing:
This article was originally published in Clinica
Diagnostics developer Cozart has won a contract with the UK Home Office for laboratory oral fluid drug confirmation testing, a deal that could boost the company's top-line by £700,000 ($1.4m) in the first year. The initial one-year, sole-supplier contract is based on a four-year framework agreement between the Abingdon, Oxfordshire-based company and the Home Office. Under the terms of the deal, Cozart will perform follow-up lab confirmation tests - if and when required - for cocaine and heroin after the samples have already been screened (using Cozart's RapiScan test) in police custody suites as part of a national drug interventions programme.
You may also be interested in...
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.